Sanofi

Open: 47.94 Close: 47.68 Change: -0.26

How to get information about Sanofi Stock without reading the whole internet.

The game is changing. There is a new strategy to evaluate Sanofi fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Sanofi are: Sanofi, Maze, SA, deal, French, drugmaker, business, and the …

Concept Map

Semantic Network

Stock Summary

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company also provides cough, cold.

Today's Summary

French drugmaker cancels deal to license Maze Therapeutics Inc. Maze alleges the transaction would protect Sanofis. monopoly. Maze was to get an upfront payment of $150M.

Today's News

troubled sanofi plant leaked dangerous neurotoxin last month. The facility, located in Mourenx, stopped production “immediately after noting “inconsistent measurements” of bromopropane emissions. Sanofi SA said Monday it was canceling plans to license Maze Therapeutics Inc. Sanofi and Maze inked a licensing deal in early May for the latters glycogen synthase 1 (G1) program MZE001 which is being developed for the treatment of Pompe disease. Sanofi terminating deal with Maze in accordance with its terms. Maze was to get an upfront payment of $150M from Sanofi ( SNY ) and eligibility to get up to an additional $600M in milestone payments. Maze alleges the transaction would protect Sanofis. monopoly. French drugmaker to swap animal-health business for German firms consumer health-care unit. Sanofi SA said it has entered exclusive negotiations with Boehringer Ingelheim GmbH on a possible exchange of its animal-Health business for most of the German groups consumer health care business. Sanofi shares skid as French drugmaker outlines higher R&D expenses, taxes. Sanofi Sees Annual Sales From New Pharma Assets Above $10.8 Bln by 2030. Fitch withdraws Sanofi Ratings on Commercial Reasons. AstraZeneca, Sanofi enter expanded supply deal for RSV Shots in US. AstaZeneca and Sanofi set to deliver additional doses of their jointly developed respiratory syncytial virus vaccine. Sanofi al­ready markets Nexvi­azyme, a suc­ces­sor to its own My­ozyme/Lu­mizyme. Maze held a promising Phase 1 asset (MZE001) The FTC characterizes Sanofi as the “monopolist supplier of drugs used to treat Pompe disease” Sanofi S.A. per Employee €473.87K P/E Ratio 12.79P/E ratio. Sanofi shares slump as French drugmaker outlines higher R&D expenses, taxes.

Stock Profile

"Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as dupixent, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers body lotions, anti-itch products, moisturizing and soothing lotions, body and foot creams, and eczema powders. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for Parkinson's disease; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Amunix Pharmaceuticals, Inc for T-cell engagers and cytokine therapies. It also enters in a strategic collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France."

Keywords

How much time have you spent trying to decide whether investing in Sanofi? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Sanofi are: Sanofi, Maze, SA, deal, French, drugmaker, business, and the most common words in the summary are: sanofi, bloomberg, maze, news, ftc, drug, market, . One of the sentences in the summary was: Maze was to get an upfront payment of $150M.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #sanofi #bloomberg #maze #news #ftc #drug #market.